Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. Hypertension. 2005; 46: 156-161.
Dominiczak AF, Bohr DF. Nitric oxide and hypertension in 1995. Curr Opin Nephrol Hypertens. 1996; 5: 174-180.
Ducloux D, Kazory A, Chalopin JM. Maladie coronaire en transplantation rénale: comment apprécier et prendre en charge le risqué coronarien? En: Lesavre P, Drüeke T, Legendre C, Niaudet P, eds. Actualités Néphrologiques Jean Hamburger, Hôpital Necker. Paris, Paris, Flammarion Médicine-Sciences, 2007:91-103.
Dyer AR, Elliott P, Shipley M, Stamler R, Stamler J. Body mass index and associations of sodium and potassium with blood pressure in INTERSALT. Hypertension. 1994; 26: 729-736.
Eide IK, Torjesen PA, Drolsum A, Bobovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004; 22: 2217-2226.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007. 369: 201-207.
Estacio R.O, Jeffers BW, Hiatt WR., Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338: 645-652.
Fagard RH. The role of exercise in blood pressure control: Supportive evidence. J Hypertens. 1995: 1995; 13: 1223-1227.
Fardella CE. Bases Clínico Moleculares de la Hipertensión Arterial Mineralocorticoidea. Nefrología Latinoamericana. 2004; 11: pp. 82
Feringa HH, Bax JJ, van Waning VH, Boersma E, Elhendy A et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. Arch Interm Med. 2006; 13: 166: 529-535.
Fernandez-Fernandez JM, Tomás M, Vázquez E, Orio P, Latorre R, Senti M, et al. Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J Clin Invest. 2004; 113: 1032-1039.
Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al. Impact of overweight on risk of developing common chronic diseases during a 10-years period. Arch Intern Med. 2001; 161: 1581-1586.
Field AE, Cook NR, Gillman MW. Weight status in childhood as a predictor of becoming overweight or hypertensive in early adulthood. Obesity Research. 2005; 13: 163-169.
Fillmore KM, Stockwell T, Chikritzhs T, Bostrom A, Kerr W. Moderate alcohol use and reduced mortality risk: systematic error in prospective studies and new hypotheses. Ann Epidemiol. 2007; 17: (Suppl 5): S16-S23.
First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol. 1994; 4 (Suppl 8): S30-S36.
Fishel RS, Eisenberg S, Shai SY, Redden RA, Bernstein KE, Berk BC. Glucocorticoids induce angiotensina-converting enzyme expression in vascular smooth muscle. Hypertension. 1995; 25: 343-349.
Fleming I, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda). 2005; 20: 91-95.
Fournier A, Fievet P, el Esper I, el Esper N, Vaillant P, Gondry J. Hypertension and pregnancy. Diagnosis, physiopathology and treatment. Schweiz Med Wochenschr. 1995; 125: 2273-2298.
Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl.. 1999; 17: S29-S36.
Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730-1737.
Gabbai FB. Renal reserve in patients with high blood pressure. Semin Nephrol. 1995; 15: 482-487.
Ganne S, Arora SK, Dotsenko O, McFarlane SI, Whaley-Connell A. Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep. 2007; 7: 208-217.
García JL. Radicales libres e hipertensión arterial. Boletín Informativo Sociedad Venezolana de Nefrología. 1997; 1:1.
Gasowski J, Fagard RH, Staessen JA, Grodzicki T, Pocock S, Boutitie F et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens. 2002; 20: 145-151.
Gifford RW. Antihypertensive therapy. Angiotensin-Converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. Med Clin North Am. 1997; 81: 1319-1333.
Gilbert JS, Cox LA, Mitchell G, Nijland MJ. Nutrient-restricted fetus and the cardio-renal connection in hypertensive offspring. Expert Rev Cardiovasc Ther. 2006; 4: 227-237.
Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG. Stroke and alcohol consumption. N Engl J Med. 1986; 315:: 1o41-1046.
Gonzalo A, Gallego A, Rivera M, Orte L, Ortuño J. Influence of hipertensión on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron. 1996; 72: 225-230.
González-Posada Delgado JM, Hernandez Marrero D, Rufino Hernandez . Complicaciones Médicas. Morbilidad y mortalidad cardiovascular tras el trasplante renal. En: Ortega F, Arias M, Campistol JM, Matesanz R, Morales JM, eds. Trasplante Renal. Madrid, Madrid, España: Editorial Medica Panamericana, 2007: 186-193.
Gordjani N, Offner G, Hoyer PF, Brodehl J. Hypertension after renal transplantation in patients treated with cyclosporin and azathioprine. Arch Dis Child. 1990; 65: 275-279.
Gordon T, Kannel WB. Drinking habits and cardiovascular disease: the Framingham Study. Am Heart J. 1983; 105: 667-673.
Grantham JJ. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int Suppl. 1997; 63: S93-S97.
Grünfeld JP, Legrain S. Quelles maladies rénales peut-on prévenir? Actualités néphrologiques de l'hopital necker. Flammarion Médecine-Scienes Paris. 1979; 291-317.
Guidelines Sub-Committee. 1999 World Health Organization/International Society of
Hypertension Guidelines for the management of hypertension. J Hypertens.
1999;17:151183.
Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinina assay. Am J Kidney Dis. 2004; 44: 84-93.
Hansson L, Zanchetti A, Carruthers S, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HTO) randomised trial. Lancet. 1998; 351; 1755-1762.
Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999; 353: 103-107.
Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension. 1998; 31: 266-270.
He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight. JAMA. 1999; 282: 2027-2034.
He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Herat J. 1999; 138: S211-S219.
Hernández D, Lacalzada J, Salido E, Linares J, Barragán A, Lorenzo V, et al. Regresión of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int. 200; 58: 889-897.
Hernandez R, Carvajal AR, Armas M.J, Armas MC. Platelet aggregation in arterial hypertension. Invest Clin. 1997; 38 (Suppl 2): S41-S46.
Higgins JR, de Swiet M. Blood-pressure measurement and classification in pregnancy. Lancet. 2001; 357: 131-135.
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777-1782.
Holzgrene H. Treatment of hypertension in the elderly. Drugs. 1993; 46 (Suppl 2): S24-S31.
Hörl WH. ACE inhibitors and the kidney. Wien Med Wochenschr. 1996; 146: 234-235.
Howard BV, Rodríguez BL, Bennett PH, Harris MI, Hamman R, Kuller LH, et al. Prevention ConferenceVI: Diabtes and Cardiovascular Disease: Writing Group I: epdidemiology. Circulation. 2002; 105 (18): e132- e137.
Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165: 923-928.
Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, et al. Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension. J Hypertens. 2006; 24: 889-894.
Huysmans FT, Hoitsma AJ, Koene RA. Factors determining the prevalence of hypertension after renal transplantation. Nephrol Dial Transplant. 1987; 2: 34-38.
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005; 45: 198-2002.
Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996; 49: 800-805.
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003; 63: 1468-1474.
Isles CG. Management of hypertensive crises. Scott Med J. 1995; 40: 23-25.
Ito S. Kidney and hypertension: role of the yuxtaglomerular apparatus. Tohoku J Exp Med. 1997; 181: 411-429.
Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewski T, et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003; 92: 637-643.
Jacobson H. Ischemic renal disease. Kidney Int. 1988; 34: 729-743.
Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Aterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000 ; 35: 898-903.
Jindra A, Hork K. Molecular genetics methods in the study of hereditary essential hypertension. Cas Lek Cesk. 1998; 137: 39-43.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet; 2004: 363: 2022-2031.
Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1-induced vasopressor responses in essential hypertension. Hypertension. 1997; 30: 15-21.
Kannel WB, Belanger AJ. Epidemiology of heart failure. Am J Heart J. 1991; 121: 951-957.
Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J. 1991; 121: 1268-1273.
Kaplan NM. 1994. Treatment of hypertension. In: Kaplan NM, ed. Clinical Hypertension. Baltimore, Maryland: Williams&Wilkins; 1994: 191-280.
Kaplan N, Whisenant BK, Czarnecki MJ. Management of hypertension: update in therapeutics (JNC-6). American College of Cardiology. 1998: March 29- April1.
Kario K, Kanai N, Nishiuma S, Fujii T, Saito K, Matsuo T, et al. Hypertensive nephropathy and the gene for angiotensin-converting enzyme. Arterioscler Thromb Vasc Biol. 1997; 17: 252-256.
Kasiske BL. Possible causes and consequences of hypertension in stable renal transplant patients. Transplantation. 1987; 44: 639-643.
Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004; 43: 1071-1081.
Khalili P, Nilsson PM, Nilsson JA, Berglund G. Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. J Hypertens. 2002; 20: 1759-1764.
Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-Therapy. Can J Cardiol. 2007; 23: 539-550.
Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of a transforming factor beta-dependent mechanism of inhibition of cell growth. Transplantation. 1994; 57: 577-582.
King DE, Everett CJ, Mainous AG, Liszka HA. Long-term prognostic value of resting heart rate in subjects with prehipertensión. Am J Hypertens. 2006; 19: 796-800.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334: 13-18.
Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia (Cochrane Review). En: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
Kobrin I, Charlon V, Bursztyn M. New developments in drug therapy of hypertension. Med Clin North Am. 1997; 81: 1359-1371.
Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, et al. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. J Pharmacol Exp Ther. 2004; 309: 275-284.
Krekels MM, van Es PN, Leunissen KM, De Leeuw PW. Sodium sensitivity of blood pressure in hypertensives is not related to sodium, but rather to renin. J Hum Hypertens. 1996; 10 (Suppl 3): S127-S130.
Krishan I. Epidemiología de la hipertensión: definición, determinantes y riesgos. En: Rodicio JL, Romero JC, eds. Tratado de Hipertensión. Barcelona, Barcelona: Salvat Editores S.A; 1986: 1-9.
Lane DA, Shah S, Beepers DG. Low-dose spironolactone in management of resistant hypertension: a surveillance study. J Hypertens. 2007; 25: 891-894.
Langer RD, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation. 1992; 85: 910-915.
Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA. 1985; 253: 657-664.
LaPalio LR. Hypertension in the elderly. Am Fam Physiciam. 1995; 52: 1161-1165.
Laragh JH. The renin system and the impact of ACE inhibition for understanding, diagnosis, and treatment of hypertension. En: Sonnenblick EH, Laragh JH, Lesch M. eds. New Frontiers in Cardiovascular Therapy. Princeton, NJ: Excerpta Medica; 1989: 84-116.
Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236-1241.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure?I-Analysis of observational data among populations. BMJ. 1991; 302: 811-815.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III-Analysis of data from trials of salt reduction. BMJ. 1991; 302: 819-824.
Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension. 2004; 44: 796-799.
Lee YS, Lee BH, Park SJ, Kang SB, Rhim H, Park JY, et al. 3,4-Dihydroquinazoline derivates as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004; 14: 3379-3384.
LeLorier J. The value of lowering blood pressure. Can J Cardiol. 2006; 22: 63-64.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensina-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462.
Lindholm L, Ejlertsson G, Schersten B. High risk of cerebro-cardiovascular morbidity in well treated male hypertensives: a retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med Scand. 1984; 216: 251-259.
Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875-876.
López-Menchaca R, Suárez Fernández C. Nuevos fármacos hipotensores. Nefrología e Hipertensión. 2007; 3: 274-288.
López Rivera JA. Programa para detección, evaluación y tratamiento del paciente hipertenso. Tachira, San Cristóbal, Venezuela: PROIMPRE, C.A.; 2004: pp. 33.
Lubsen J, Wagener C, Kirwan B-A, Bouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005; 23: 641-648.
Luque Otero M, Martell Claros M, Ruiz Fernández MD, Fernández-Cruz A, Fernández Pinilla C. Medidas no farmacológicas en el tratamiento de la hipertensión esencial. Rev Clin Esp. 1986; 179 (suppl 1): S46-S50.
Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated hypertension. Am J Hypertens. 1999; 12: 541-547.
Magee LA, Ornstein MP, Von Dadelszen P. Management of hipertensión in pregnancy. BMJ. 1999; 318: 1332-1336.
Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003; 14: 1164-1174.
Mailloux LU, Napolitano B, Bellucci AG, Vernance M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease: incidence, clinical correlates and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994; 24: 622-629.
Maisch B, Brilla C, Kruse T. Directions in antihypertensive treatment-our future from the past. Eur Heart J. 1995; 16 (Suppl C): S74-S83.
Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic síndrome in th Presión Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007; 49: 40-47.
Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007; 25: 1105-1187.
Mancia G, Grassi G. European, American and British Guidelines: similarities and differences. In: Black HR, Elliott WJ, eds. Hypertension. A companion to Braunwald"s Heart Diseases. Amsterdam: Saunders-Elsevier, 2007: 571-575.
Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006; 24: 3-10.
Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Hennig M, et al. Assessment of long-term antihypertensive treatment by clinic an ambulatory blood pressure. Data from the ELSA Study. J Hypertens. 2007; 25: 1087-1094.
Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005; 42 (Suppl 1): S17-S25.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134: 629-636.
Marmot MG, Rose G, Shipley MI, Thomas BJ. Alcohol and mortality: a U-shaped curve. Lancet. 1981; 1: 580-583.
Marin R, Gorostidi M, Pobes A. Hipertensión arterial y enfermedad vascular renal: nefroangioesclerosis. Nefrología. 2002; 22 (Suppl 1): S36-S45.
Martinez-Perez ME, Hughes AD, Stanton AV, Thom SA, Chapman N, Bharath AA, et al. Retinal vascular tree morphology: a semi-automatic quantification. IEEE Trans Biomed Eng. 2002; 49: 912-917.
Matavelli LC, Zhou X, Frohlich ED. Hypertensive renal vascular disease and cardiovascular endpoints. Curr Opin Cardiol. 2006; 21: 305-309.
McCarthy R. The pharmacologic treatment of hypertension: an update. Drug Benefit Trends. 1997; 9: 71-77.
McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006; 332: 1177-1181.
McIntyre M, Dominiczak AF. Nitric oxide and cardiovascular disease. Postgrad Med J. 1997; 73: 630-634.
McLaughlin K, Jardine AG, Moss JG. Renal artery stenosis. BMJ. 2000; 320: 1124-1127.
Mengden T, Schwartzkopff B, Straner BE. What is the value of home (self) blood pressure monitoring in patients with hypertensive heart disease ? Am J Hypertens. 1998; 11: 813-819.
Menon S, Berezny KY, Kilaru R, Benjamin DK, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fisinopril in hypertensive children. Am Heart J. 2006; 152: 394-399.
Messerli FH, Grossman E, Goldbourt U. Are b-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998; 279: 1903-1907.
Miralles M, Covas MI, Martinez-Miralles E, Cairols M, Cotillas J, Santiso MA. Captopril test and renal duplex scanning for the primary screening of renovascular disease. Am J Hypertens. 1997; 10: 1290-1296.
Modan H, Halkin H, Amog S, Lusky A, Eskol A, Shefi M et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985; 75: 809-817.
Modesti PA, Morabito M, Bertolozzi I, Massetti L, Panci G, Lumachi C, et al. Weather-related changes in 24-hour blood pressure profile: effects of age and implications for hypertension management. Hypertension. 2006: 47: 155-161.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982; 285: 685-688.
Moore LL, Visioni AJ, Qureshi M, Bradlee ML, Ellison C, D'Agostino R. Weight loss in overweight adults and the long-term risk of hypertension: The Framingham Study. Arch Intern Med. 2005; 165: 1298-1303.
Morales JM, Dominguez-Gil B, Gutierrez MJ. Impact of immunosuppression in the cardiovascular risk profile after renal transplantation. Nefrología. 2006; 26: 181-194.
Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension?. JAMA. 1998; 279: 1813-1816.
Moutquin JM, Garner PR, Burrows RF, Rey E, Helewa ME, Lange IR et al. Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. CMAJ. 1997; 157: 907-919.
Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, Stampfer MJ, Willet WC. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003; 348: 109-118.
Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006; 1: 221-228.
Nadal MA. Hipertensión arterial y embarazo. En: Rodicio JL, Romero JC, eds. Tratado de HIPERTENSION. Barcelona, BA: Salvat; 1986: 355-368.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361: 117-124.
National Cholesterol Education Program. Third Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adul Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
National Institutes of Health. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication Nº 93. 1993: 1088.
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000; 356: 1955-1964.
Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003; 42: 878-884.
Neutel JM, Smith DHG. The role of low-dose combination therapy in the management of hypertension: an alternative approach. Hospital Medicine. 1998; 34: 35-43.
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. CAMELOT Investigators. Effect of antihypertensive agent on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217-2225.
Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997; 1873-1879.
Nordlander M, Sjöquist PO, Ericsson H, Rydén L. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipino, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004; 22: 227-250.
Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006; 48: 739-751.
Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000; 35: 539-543.
Oh BH, Mitchell, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007; 49: 1157-1163.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004; 292: 2343-2349.
O"Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 14-22.
Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinicl trials of fish oil supplementation in high risk pregnancies. BJOG. 2000; 107: 382-395.
Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens. 2004; 18: 453-459.
Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens. 2006; 24: 775-781.
Ong AC. Bases Moléculaires de la formation de kystes dans la polykystose rénales autosomique dominante. En: Lesavre P, Drüeke T, Legendre C, Niaudet P eds. Actualités Néphrologiques Jean Hamburger, Hôpital Necker. Paris, Francia. Flammarion Médicine-Sciences; 2006: 5-18.
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007: 370: 221-229.
Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004; 22: 1435-1438.
Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996; 15: 72-78.
Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Interm Med. 2002; 162: 2313-2321.
Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002; 347: 1256-1261.
Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol. 1997; 20(Suppl 2): S26-S33.
Paradisi G, Biaggi A, Savone R, Ianniello F, Tomei C, Caforio L, et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab. 2006; 91: 1233-1238.
Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med. 1996; 335: 1682-1683.
Peacock ME, Park DS, Swiec GD, Erley KJ. Perioral angioedema associated with angiotensina-converting enzyme inhibitor. J Periodontol. 2005; 76: 651-654.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapirl Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805-2816.
Perera GA. Hypertensive vascular disease: description and natural history. J Chronic Dis. 1955; 1: 33-42.
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-766.
Pickering TG. Modern definitions and clinical expressions of hypertension. In: Laragh JH, Brenner BM, eds. Hypertension, pathophysiology, diagnosis, and management. New York, NY: Raven Press; 1995: 17-21.
Pickering TG. 1998. Optimal blood pressure levels. Am J Hypertens. 1998; 11: 877-878.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.
Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31: 823-829.
Pourdjabbar A, Lapointe N, Rouleau JL. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes? Can J Cardiol. 2002; 18( Suppl A): 7A-14A.
Predel HG, Kipnowski J, Meyer-Lehnert H, Arendt RM, Kramer HJ. Human atrial natriuretic peptide in non-dialysed patients with chronic renal failure. Clin Nephrol. 1989; 31: 150-155.
Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. Lancet. 1987; 1: 647-651.
Qiu CC, Zhou WY. Susceptible genes of essential hypertension. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006; 28: 284-288.
Qureshi AI, Fareed K, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehipertensión a risk factor for cardiovascular diseases ?. Stroke. 2005; 36: 1859-1863.
Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006; 144: 172-180.
Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension. 1998; 31: 189-193.
Reaux-Le Goazigo A, Iturrioz X, Fassot C, Claperon C, Roques BP, Llorens-Cortes C. Role de angiotensin III in hipertensión. Curr Hypertens Rep. 2005; 7: 128-134.
Reboldi G, Gentile G, Angeli F, Verdecchia P. Microalbuminuria and hypertension. Minerva Med. 2005; 96: 261-275.
Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens. 2002; 20: 353-355.
Rossetti S, Burton S, Strmecki L, Pond GR, San Millan JL, Zerres K, et al. The position of the kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol. 2002; 13: 1230-1237.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941-1951.
Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens. 1993; 2: 962-967.
Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer Mj, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for Study of Diabetes (EASD). Eur Heart J. 2007; 28: 88-136.
Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001; 344: 431-442.
Safian RD. Atherosclerotic renal artery stenosis. Curr Treat Options Cardiovasc Med. 2003; 5: 91-101.
Samuelsson O. Hypertension in middle-age men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand Suppl. 1985; 702: 1-79.
Sanders PW. Salt-sensitive hypertension: lessons from animal models. Am J Kidney Dis. 1996; 28: 775-782.
Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116: 85-97.
Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke .2003; 34: 1699-1703.
Seidell JC, Visscher TL, Hougeveen RT. Overweight and obesity in the mortality rate data: current evidence and research issues. Med Sci Sports Exerc. 1999; 31 (Suppl 11): S597-S601.
Shemin D, Dworkn LD. Sodium balance in renal failure. Curr Opin Nephrol Hypertens. 1997; 6: 128-132.
Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006; 145: 237-246.
Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990; 162: 960-966.
Sica DA, Black HR. Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensina receptor blocker therapy. Congest Heart Fail. 2002: 8: 334-341.
Smith MC, Barrows S, Meibohm A, Shahinfar S, Simpson RL, Weigel K, et al.The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens. 1995; 8: 1177-1183.
Soubrier F, Lathrop GM. The genetic basis of hypertension. Curr Opin Nephrol Hypertens. 1995; 4: 177-181.
Spinnato JA, Freire S, Pinto E Silva JL, Cunha Rudge MV, Martins-Costa S, Koch MA, Goco N, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol. 2007; 110: 1311-1318.
Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355: 865-872.
Staessen JA, Li Y, Richart T. Oral renin inhibitors. 2006; 368: 1449-1456.
Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003; 21: 1055-1076.
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-444.
Stanton A, Jensen C, Nussberger J, O"Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137-1143.
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function measured and estimated glomerular filtration rate. N Eng J Med. 2006; 354: 2473-2483.
Tanira MO, Al Balushi KA. Genetic variations related to hipertensión: a review. J Hum Hypertens. 2005; 19: 7-19.
Textor SC. Revascularisation in atherosclerotic renal artery disease. Kidney Int 1998; 53: 799-811.
, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007; 33:414-421.
Tuomiletho J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet. 2001; 357: 848-851.
US Renal Data System: Annual Data report. Bethesda, MD, The National Institute of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 1996.
Van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006; 24: 2299-2304.
van de Ven PJG, Kaatee R, Beutler JJ, Beek FJ, Woittiez AJ, Buskens E et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999; 353:282-286.
von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000; 355: 87-92.
Vandermeersch S, Stefanovic V, Hus-Citharel A, Ardaillou R, Dussaule JC, Chansel D. AT1 receptor expression glomeruli from NO-deficient rats. Nephron Exp Nephrol. 2003; 95: 19-28.
Venkateswara K. Complicaciones médicas postrasplante. Surg Clin Northe Am.1998: 107-125.
Verdecchia P, Angeli F, Achilli P, Castellani C, Broccatelli A, Gattobigio R, et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol. 2007: 22: 329-334.
Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003; 16: 895-899.
Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46: 386-392.
Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002; 287: 1003-1010.
Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004; 13: 93-99.
Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simon-Morton DG et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001; 135: 1019-1028.
Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003; 139: 901-906.
Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998; 19: 5-8.
Whelton PK, Lawrence J A, Espeland MA, Applegate WB, Ettinger WH, Kostis JB. et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279: 839-846.
Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002; 288: 1882-1888.
Williams GH. Hypertensive vascular disease. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill, Inc; 1994: 1116-1132.
Williams HG, Fisher NDL. Genetic approach to diagnostic and therapeutic decisions in human hypertension. Curr Opin Nephrol Hypertens. 1997; 6: 199-204.
Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113: 664-670.
Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA. 2002; 287: 1153-1159.
Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE. Et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293: 1595-1608.
Yu SH, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: aetiology and outcome in 83 patients. Clin Exp Hypertens A. 1986; 8: 1211-1213.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952.
Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens. 2007; 25: 747-750.
Zucchelli P, Zuccalá A. Hypertension and renal dysfunction. Curr Opin Nephrol Hypertens. 1996; 5: 97-101.
AGRADECIMIENTOS
A la TSU. Coromoto Belandria por su desinteresada ayuda en la diagramación de este texto.
DEDICATORIA
Los autores dedican este texto a los Dr(s): Hernán Díaz, Yamirla Quintero. Shakira Parra, Mylene Sayago y Liubik Nerey, Residentes del Postgrado de Nefrología de la Universidad de Los Andes por su colaboración con los programas de la Unidad de Nefrología, Diálisis y Trasplante Renal del Instituto Autónomo Hospital Universitario de Los Andes.
Autor:
Miguel Rondon Nucete
Dra. Onelia Orence Leonett
Dra. Ana Verónica Rondon Guerra
Licenciada Ana O. Guerra de Rondon
| Página siguiente |